Fan Xiaoqi sorting
(New York Composite Television)Partner Germany Biontech announced on Tuesday that they have begun to test the new version of the new version of Omikon, which fights coronal diseases.
Pfizer and Biontech will explore in clinical trials. The immune response caused by the new vaccine in those who have not vaccinated the crown disease, and the effectiveness it has played in the previous vaccination.
The two companies said that this clinical trial started in the United States. There were more than 1,400 volunteers from 18 to 55 years old., Side effects and immune response.
It is understood that volunteers participating in clinical trials are divided into three groups.In the first group of the existing Pfizer crown vaccine from 90 days to 180 days before the test, they will vaccinate one to two doses for Omikon vaccine.The second group was vaccinated from 90 days to 180 days before participating the test, and the existing Pfizer vaccine would be vaccinated, or the Omikon vaccine was vaccinated.The third group is those who have never been vaccinated with coronary diseases, and they will vaccinate three doses of Omikon vaccine.
Pfizer predicts that preliminary research results can be obtained in the first half of this year.Biontech said that because regulators need more clinical trial data, the new version of vaccine should not be launched at the end of March this year.Pfizer previously revealed that the Omikon vaccine was as soon as possible to start mass production in March.
The director of Pfizer's responsible for the research and development of the vaccine, Jen Sen, said in a statement that although the data shows that the vaccine added to the primitive coronary strain can prevent Omikon from causing severe illnesses and hospitalization, but still need to plan aheadEssence
"We must be prepared for the effect of vaccine protection over time, and the situation of the new variant strains that may occur in the future."
The world has passed the world 2100 in the past week 2100 a week.Thousands of people are confirmed to be innovative
According to the latest US research report, the epidemic caused by Omikon does not seem to be serious when Delta and others are coming.There are fewer cases of death, but Omikon has a stronger communication power, which has set off a record of records of infection and hospitalization, resulting in the U.S. medical system is not overloaded.
A research report published by the Centers for Disease Control and Prevention on Tuesday pointed out that although the number of infected people in this wave of Omikon is soaring, the number of cases sent to the intensive care unit is compared to last year than last year.In the peak of the winter epidemic, it was about 29%lower, and it was about 26%lower than the Delta epidemic.
Studies have shown that the ratio of Omikon is low, which may be related to the high vaccine coverage, inoculating enhanced agents, and the immune protection of some people after rehabilitation.
Nevertheless, the World Health Organization warned that the Omikon outbreak still pose a major threat.The organization pointed out in the report of crown disease every week on Tuesday night that the new high in the world's new crown disease confirmed in the past week has reported a new high, and countries have reported more than 21 million new confirmed cases.The highest number of cases.In addition, from the samples collected in the past 30 days, the genome sequences were completed, and uploaded to the virus gene sequence of the global influenza shared database, Omiro accounted for 89.1%, and Delta only accounted for 10.7%.
